4b6l: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design== | |||
<StructureSection load='4b6l' size='340' side='right' caption='[[4b6l]], [[Resolution|resolution]] 1.90Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4b6l]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4B6L OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4B6L FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=9ZP:4-[[(4R)-5-CYCLOPENTYL-4-ETHYL-3A,4-DIHYDRO-3H-[1,2,4]TRIAZOLO[4,3-F]PTERIDIN-7-YL]AMINO]-N-CYCLOPROPYL-3-METHOXY-BENZAMIDE'>9ZP</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Polo_kinase Polo kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.21 2.7.11.21] </span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4b6l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4b6l OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4b6l RCSB], [http://www.ebi.ac.uk/pdbsum/4b6l PDBsum]</span></td></tr> | |||
</table> | |||
== | ==See Also== | ||
[[ | *[[Serine/threonine protein kinase|Serine/threonine protein kinase]] | ||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Polo kinase]] | [[Category: Polo kinase]] | ||
[[Category: Brown, K | [[Category: Brown, K]] | ||
[[Category: Charrier, J D | [[Category: Charrier, J D]] | ||
[[Category: Durrant, S | [[Category: Durrant, S]] | ||
[[Category: Griffiths, M | [[Category: Griffiths, M]] | ||
[[Category: Hudson, C | [[Category: Hudson, C]] | ||
[[Category: Kay, D | [[Category: Kay, D]] | ||
[[Category: Knegtel, R | [[Category: Knegtel, R]] | ||
[[Category: ODonnell, M | [[Category: ODonnell, M]] | ||
[[Category: Pierard, F | [[Category: Pierard, F]] | ||
[[Category: Twin, H | [[Category: Twin, H]] | ||
[[Category: Weber, P | [[Category: Weber, P]] | ||
[[Category: Young, S | [[Category: Young, S]] | ||
[[Category: Kinase inhibitor]] | [[Category: Kinase inhibitor]] | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
[[Category: Water-mediated h-bond]] | [[Category: Water-mediated h-bond]] | ||
Revision as of 09:58, 21 December 2014
Discovery of Oral Polo-Like Kinase (PLK) Inhibitors with Enhanced Selectivity Profile using Residue Targeted Drug Design
| ||||||||||||